Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Medical bottles and syringes are seen with the Novo Northisco shift on a screen in the background.
Nurphoto | Nurphoto | Getty images
Stock of Nine noralymous Rose 4.5% Wednesday after the network of the fourth quarter for their wegovy obesity drug, but predicting a slowdown slowdown for 2025.
Profit Nept at the pharmaceutical pharmactic of 1% year to 28,23 Billion Danish Kroner ($ 3.98 billion in the fourth Danish Danish Kroner anticipated.
KRONER KRONER Kroner Kroner’s profit, also Kroner, also beat 99,14 Billion Danish Kroner for 2024.
The action were the 4.5% in offers before Wednesday.
The Maker Drug has posted a 107% Of it Year increases in year to sale at 19.87 Billion Kroner Kroner) in the end of 3.02 Billion Danish Kronor
Sell generally to the company – that also produces rare diseases – increased rare diseases in the fourth quarter and 26% on the year in constant exchange rates. That growth has been kept mainly by the request by North America and Europe, the Oriental Medium and Africa’s regions.
Nine Northern, however, the foreigner’s forecast growth forecast for 24% to the exchange of exchange, under 18% to the company’s competition, company and reflects “Market of the diabetes and obesity. “
NO NORCHISH TURKED a wave of rising global global request for GLP-1 agonity obesity treatments. Glp-1s, who form the base of the wegovy and the rival of novo Lilly eli‘S Zepbound, work mimiting a hormone named the peptide-like the pepper-1, which suppreses the appetite.
Inverso are now looking at the updates about the other obesity drug cancells, including their experimental cagrisema treatment calmly. The results of late-stage corrisema DECALL The markets in December after showing reduction of the average weight of 22.7%, under 25% of 25% had previously planned.
The main dealty results a sudden to which cagering could tell the next generation drug, semagment-combination – active ingredient in wegovy, a harassment of wasteful loss treatment.
However, positive Results at the first stage For their Obesity Drugs in the evening, that simply the hormone of Amylin pancreas, drove the highest stock last month.
IO N Nordisk told wednesday that will make a further study in 2025 with a view to fool for regulative approval in the first quarter of 2026, according to Reuters.
This is a news story and will be updated soon.
